
CONTENTS

December 2009 volume 6 no. 12



RESEARCH HIGHLIGHTS

- 675 CYP2D6 polymorphisms associated with tamoxifen outcome
- 676 Treating advanced TCCU
- 676 Aberrant methylation—early biomarker for CRC
- 677 Interstitial fluid pressure predicts radiation response
- 677 Fas determines outcome in DLBCL
- 677 High dose equals improved response
- 678 Diagnostic markers for ovarian cancer
- 678 Dexamethasone for childhood leukemia

NEWS & VIEWS

679 TARGETED THERAPIES: Sunitinib in RCC—expanded access equals expanded benefit? Toni K. Choueiri and Michael B. Atkins

680 HEMATOLOGY: Dasatinib regimens for patients with chronic myeloid leukemia François Guilhot and Lydia Roy

- 682 screening: Is breast cancer overdiagnosed? Andrea Veronesi and Diego Serraino
- 683 HEMATOLOGY: First-line bortezomib benefits patients with multiple myeloma

Meletios A. Dimopoulos and Evangelos Terpos



Theoretical models of breast subtypes p718

Continuing medical education in association with our CME provider MedscapeCME. Full details in article.



On the Nature Reviews Clinical Oncology website www.nature.com/reviews/clinonc

Advance Online Publication

We operate an Advance Online Publication (AOP) service for authors and readers to view the latest review articles published online ahead of print.

Enhanced PDFs

All email addresses and websites are live links in the online PDFs; bookmarks are also provided for easy navigation.

PowerPoint slides

Figures and tables can be downloaded as PowerPoint files for use in presentations and for teaching.

E-alert sign-up

Get FREE monthly e-mail alerts to the content of this journal by registering online. Or sign up to receive the latest content as an RSS newsfeed by visiting www.nature.com/reviews/clinonc

Online-only content

Supplementary information

Articles may include online-only supplementary text or display items, which may be referenced separately from the article.

About the authors

Biographies for authors are available in the online versions of articles.

REVIEWS

687

CME

Liver metastases from colorectal cancer: radioembolization with systemic therapy

Nils H. Nicolay, David P. Berry and Ricky A. Sharma Most patients with advanced colorectal cancer die from hepatic metastases. Radioembolization is a technique for administering radiotherapy internally to unresectable primary or secondary hepatic malignancies in a single procedure to improve local control of disease. This technique enables significant downsizing of liver metastases after surgical resection, and the rationale for this approach combined with cytotoxic and molecularly targeted agents is outlined.

699 Primary HPV screening for cervical cancer prevention: results from European trials

Elsebeth Lynge and Matejka Rebolj

Six European randomized controlled trials that with compare human papillomavirus (HPV) testing with cytology testing for cervical screening are under way. The outcome of HPV testing versus cytology testing depends not only on the relative accuracy of the primary test but also on how radical the different triage procedures are. Two trials have shown a 50% reduction in grade 3 cervical intraepithelial neoplasia detection in subsequent screening rounds. The authors critically discuss the reasons for the different results observed in these trials and the implications for primary screening.

707 Gamma-delta T-cell lymphomas

Claudio Tripodo, Emilio Iannitto, Ada Maria Florena, Carlo Ennio Pucillo, Pier Paolo Piccaluga, Vito Franco and Stefano Aldo Pileri

Gamma-delta lymphomas are rare and aggressive lymphomas with a poor prognosis. The authors of this Review discuss the clinical and biological features of the two types of such lymphomas and the diagnostic challenges associated with these still insufficiently known diseases.

718 Histological and molecular types of breast cancer: is there a unifying taxonomy?

Britta Weigelt and Jorge S. Reis-Filho

Microarray studies have been used to unravel the molecular characteristics of breast cancer and a molecular taxonomy has been proposed. The authors of this Review discuss the origins of the diversity of breast cancer and, based on the study of histological special types of breast cancer, propose an approach for the identification of novel therapeutic targets.

PERSPECTIVES

731

JZVY

OPINION: More is less—combining targeted therapies in metastatic colorectal cancer

Cornelis J. A. Punt and Jolien Tol

Targeted agents directed at VEGF and EGFR have become part of the standard treatment of metastatic colorectal cancer; however, only some patients benefit from such treatment. The CAIRO2 and PACCE trials have shown a detrimental effect of adding an anti-EGFR antibody to standard chemotherapy plus bevacizumab. In this Perspective, the authors discuss issues that may explain these unexpected results.